Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesEarnAISquareMore
Matrixport: Bitcoin Technically Oversold, Market Still Awaits Confirmation from Macroeconomic Signals

Matrixport: Bitcoin Technically Oversold, Market Still Awaits Confirmation from Macroeconomic Signals

金色财经金色财经2025/08/08 07:27
Show original

According to a report by Jinse Finance, Matrixport’s weekly analysis states: “The market has recently entered a correction phase, with Bitcoin’s momentum weakening and both liquidity and trading enthusiasm cooling off. Trading volumes have shrunk, funding rates remain low, and the market structure is becoming more relaxed. As the Federal Reserve has yet to release a clear signal, the market may continue to remain on the sidelines, entering a period of consolidation. In the very short term, oversold stochastic indicators may suggest the possibility of a technical rebound, but we remain skeptical about its sustainability and are more inclined to believe that prices will continue to move sideways. The core issue currently facing Bitcoin is whether the repricing of US economic growth expectations will trigger a rise in realized volatility. As volatility continues to decline, the net asset value (NAV) of some publicly listed companies holding large amounts of Bitcoin has contracted, weakening their ability to raise funds through new share issuance and further increase their Bitcoin holdings. For now, we still recommend exercising patience and waiting for a clear bottom signal or a renewed pickup in market momentum. In Bitcoin trading, if you don’t sell at the highs, you won’t be able to reposition at the lows.”

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Competition in US oral weight-loss drugs intensifies! Eli Lilly (LLY.US) Foundayo captures 30% of new patients, narrowing Novo Nordisk's (NVO.US) first-mover advantage

Eli Lilly stated on Monday that its oral weight-loss drug, Foundayo, has captured over 30% of the market share among new patients in the US oral obesity treatment market, narrowing the early lead achieved by Danish competitor Novo Nordisk with its Wegovy oral tablets.

智通财经2026/09/15 03:21
Competition in US oral weight-loss drugs intensifies! Eli Lilly (LLY.US) Foundayo captures 30% of new patients, narrowing Novo Nordisk's (NVO.US) first-mover advantage